An antibody specifically recognizing Pseudomonas aeruginosa PcrV and its application
By developing antibodies that specifically recognize PcrV of Pseudomonas aeruginosa, the problem of antibiotic resistance of the bacteria was solved, and effective recognition and neutralization of Pseudomonas aeruginosa was achieved, with good protective effects.
Patent Information
- Application Number
- CN202410581294.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-11
- Publication Date
- 2025-03-25
- Estimated Expiration
- 2044-05-11
AI Technical Summary
Pseudomonas aeruginosa has natural or acquired resistance to many antibiotics, which leads to difficulties in clinical treatment, especially the emergence of multidrug-resistant and pan-resistant strains, posing challenges to early effective treatment and reducing the generation of drug-resistant strains.
An antibody specifically recognizes PcrV aeruginosa PcrV is developed to achieve efficient recognition and binding of PcrV through its specific amino acid sequences of its heavy and light chain variable regions, thereby neutralizing the toxicity of Pseudomonas aeruginosa.
This antibody can specifically bind to PcrV antigen, neutralize the hemolysis of red blood cells caused by Pseudomonas aeruginosa, resist systemic invasion of Pseudomonas aeruginosa, and has a good protective effect on infection of Pseudomonas aeruginosa strain.